Infectious disease
After leading a flurry of collaborations with multiple companies to hasten the development of vaccine candidates and treatments for COVID-19, Rick Bright, the director of BARDA, has abruptly departed his post for another position in the government.
Could antibodies found in the blood of llamas, the doe-eyed South American pack animal, hold a key to developing a vaccine for COVID-19? A team of researchers from Belgium believes so.
At least some of the concern is that without greater funding and coordination, the companies won’t be able to buy sufficient raw materials, continue production of existing drugs and quickly scale up their capacity to meet the demand of new drugs and older therapies around the world.
It does not require healthcare workers and first responders to conduct the test using personal protective equipment. Therefore, it should prevent the risk of transmitting the virus.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 21, 2020.
Traditional vaccine development and regulatory policies are changing in response to the current pandemic. Some of those approaches may become more common, expanding into other, non-pandemic-related areas in the future.
GlobalData released a report that showed the global healthcare sector has been subjected to an array of cyberattacks as it deals with the COVID-19 pandemic.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 20, 2020.
Swiss pharma giant Novartis will launch a Phase III trial assessing hydroxychloroquine for the treatment of COVID-19. The trial will be conducted across the United States.
The agency issued a statement saying that it will continue its activities, such as reviewing new drug applications and clinical trial, both COVID-19 and non-COVID-19, applications, “as we do everything possible to maintain continuity of operations in a very dynamic situation.”
PRESS RELEASES